Celldex Therapeutics, Inc. $CLDX Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lowered its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 4.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 923,696 shares of the biopharmaceutical company’s stock after selling 44,920 shares during the quarter. Pictet Asset Management Holding SA owned 1.39% of Celldex Therapeutics worth $29,300,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Wellington Management Group LLP increased its holdings in Celldex Therapeutics by 39.3% during the 4th quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock worth $219,442,000 after purchasing an additional 2,279,605 shares during the period. Vanguard Group Inc. boosted its stake in shares of Celldex Therapeutics by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock valued at $109,384,000 after buying an additional 72,817 shares during the period. Bellevue Group AG boosted its stake in shares of Celldex Therapeutics by 7.6% in the 3rd quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock valued at $92,037,000 after buying an additional 250,100 shares during the period. Commodore Capital LP grew its position in shares of Celldex Therapeutics by 7.8% during the second quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock worth $70,208,000 after buying an additional 250,000 shares in the last quarter. Finally, State Street Corp grew its position in shares of Celldex Therapeutics by 19.5% during the fourth quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company’s stock worth $92,282,000 after buying an additional 555,579 shares in the last quarter.

Wall Street Analysts Forecast Growth

CLDX has been the subject of a number of recent research reports. Barclays lifted their price target on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Monday, April 20th. Wolfe Research upgraded shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 target price for the company in a research note on Monday, March 23rd. HC Wainwright reissued a “buy” rating and issued a $42.00 target price on shares of Celldex Therapeutics in a report on Monday, June 15th. Finally, Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $49.30.

Celldex Therapeutics Trading Down 0.6%

CLDX stock opened at $37.21 on Wednesday. The stock has a market cap of $2.92 billion, a P/E ratio of -8.73 and a beta of 0.95. Celldex Therapeutics, Inc. has a twelve month low of $19.72 and a twelve month high of $39.16. The company’s 50 day moving average is $32.18 and its two-hundred day moving average is $29.36.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.80 million. On average, equities research analysts predict that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.